From: Analysis of the relationship between MIR155HG variants and gastric Cancer susceptibility
Cases | Controls | p | |
---|---|---|---|
Total | 506 | 500 | |
Age | 0.229a | ||
Mean ± SD | 61.11 ± 0.50 | 60.31 ± 0.44 | |
Sex | 0.970b | ||
Male | 380 (75%) | 376 (75%) | |
Female | 126 (25%) | 124 (25%) | |
Stage | |||
I-II | 105 (21%) | ||
III-IV | 238 (47%) | ||
Absence | 163 (32%) | ||
LNM | |||
Negative | 234 (46%) | ||
Positive | 96 (19%) | ||
Absence | 176 (35%) | ||
CEA (0-20 ng/ml) | |||
Mean ± SD | 16.82 ± 10.21 | ||
SF (20-240 ng/ml) | |||
Mean ± SD | 89.05 ± 8.19 | ||
TNF (0.74–1.74fmol/ml) | |||
Mean ± SD | 1.01 ± 2.08 | ||
CA-50 (0-25 U/ml) | |||
Mean ± SD | 6.92 ± 11.30 | ||
CA-199 (0-37 U/ml) | |||
Mean ± SD | 39.70 ± 76.36 | ||
CA-242 (0-20KU/ml) | |||
Mean ± SD | 13.85 ± 27.57 | ||
AFP (0-20 ng/ml) | |||
Mean ± SD | 12.08 ± 15.33 |